Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04352101 · ClinicalTrials.gov registry record · Phase 4
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT04352101 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 18 participants.
The verdict
NCT04352101, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is designed to determine whether bupropion (vs escitalopram) increases functional connectivity (FC) within reward-related neurocircuits and decreases motivational deficits in depressed patients with increased inflammation and anhedonia. Participants will be randomized to take bupropion extended release (XL) or escitalopram for 8 weeks.
Interventions
- DRUG Escitalopram
- DRUG Bupropion XL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-09-23 |
| Est. Completion | 2022-07-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04352101
The ClinicalTrials.gov registry entry for NCT04352101 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Escitalopram is the first listed.
NCT04352101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04352101 about?
NCT04352101 is a clinical study titled "Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits". This study is designed to determine whether bupropion (vs escitalopram) increases functional connectivity (FC) within reward-related neurocircuits and decreases motivational deficits in depressed patients with increased inflammation and anhedonia. Participants will be randomized to take bupropion ex...
What is the current status of trial NCT04352101?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2020-09-23. Estimated completion is 2022-07-25.
What interventions are being tested in trial NCT04352101?
The interventions under investigation include: Escitalopram (DRUG), Bupropion XL (DRUG).
Who is sponsoring clinical trial NCT04352101?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.